Intradermal Microbotulinum Toxin for Sebum Reduction and Facial Pore Improvement

This prospective interventional study aims to assess the efficacy and safety of intradermal microdoses of botulinum toxin type A (microtoxin) for the treatment of periocular rhytids. The microtoxin technique involves the administration of highly diluted botulinum toxin in small aliquots injected superficially into the dermis, targeting fine wrinkles and improving overall skin quality without significantly affecting muscle function.

Participants presenting with periocular dynamic and static rhytids will undergo treatment with standardized microtoxin injections. Clinical evaluation will be performed using validated aesthetic scales, photographic documentation, and patient-reported outcomes. The primary outcome measure will be the degree of wrinkle reduction and improvement in skin texture. Secondary outcomes will include patient satisfaction and incidence of adverse events.

Follow-up assessments will be conducted over a defined period to evaluate both efficacy and safety. This study seeks to provide evidence regarding the clinical utility of microtoxin in periocular rejuvenation and to support its use as a minimally invasive alternative to conventional botulinum toxin techniques.

Inclusion criteria

• Adults aged 18 to 35 years
• Both male and female participants
• Presence of mild to moderate periocular fine wrinkles
• Willingness to undergo intradermal botulinum toxin injections
• Ability to provide written informed consent

Exclusion criteria

• Previous botulinum toxin treatment in the periocular area within the last 6 months
• Known hypersensitivity to botulinum toxin or its components
• Active skin infection or dermatologic disease in the treatment area
• Neuromuscular disorders
• Pregnancy or breastfeeding
• Use of medications affecting neuromuscular transmission
• History of eyelid or periocular surgery within the last 6 months